AI-Driven Drugmakers Fuel Wave of Cross-Border Deals in China
Investors are reassessing de novo drug design as firms close major business development transactions.
This year, cross-border deals in China's innovative drug sector have accelerated, with artificial intelligence-driven firms emerging as key players.
- Syneron
- Helixon
- XtalPi
These firms, together closing business development transactions worth several billion USD between March and August, illustrate the trend.
The foundations of biopharmaceutical R&D are shifting from high-volume screening and intuition-based methods toward rational design and de novo creation.
Syneron and Helixon, founded just four to five years ago, distinguished themselves in multinational pharmaceutical firms' competitive business development processes by using AI to reshape biologics R&D and improve success rates.
The deals appear to have revived investor confidence, enabling other firms in the sector to secure new funding after years of stagnation.
Author's summary: AI-driven firms accelerate cross-border deals in China's drug sector.